Sarcopenia: what slows muscle loss with age

Reviewed 19 sourcesPublished by PepVault

Strength training is the proven fix for sarcopenia; protein and creatine add to it, vitamin D helps the deficient, and no drug is approved. The trial numbers.

White-haired woman in a coral tank curls light dumbbells in fingerless gloves in a rose garden
Last reviewed
Sources
19
Questions
9
Compounds
2

The short answer

Strength training is the one treatment that reliably slows and partly reverses sarcopenia, the age-related loss of muscle strength and mass, and the ICFSR guideline strongly recommends it. Expert groups advise at least 1.0 to 1.2 g of protein per kg a day after 65, and creatine with training added about 1.4 kg more lean mass than training alone. Vitamin D helps mainly the deficient. No drug is approved.

  • Strength comes first: EWGSOP2 calls grip under 27 kg (men) or 16 kg (women), or five chair rises over 15 seconds, low.
  • Strength training added 1.1 kg of lean mass across 49 studies, and more with more volume.
  • Protein and creatine add to training; vitamin D helps mainly when blood levels are low.
  • The myostatin and activin drugs raised lean mass with no clear gain in function; testosterone's results are mixed, and none is approved for sarcopenia.

Every number checked at its primary source · · 19 sources · How we research

Evidence: Randomized trials and meta-analyses in older adults, plus the EWGSOP2 and ICFSR consensus documents: strong for resistance training, moderate for protein beside training, consistent for creatine with training, small for vitamin D and mainly in people who are deficient. Testosterone and the myostatin and activin drugs raised lean mass without a clear gain in function, and none is approved for sarcopenia; the LY2495655 and bimagrumab trials were funded by their makers.

White-haired woman in a coral tank curls light dumbbells in fingerless gloves in a rose garden

What is sarcopenia, and how is it diagnosed?

Sarcopenia is a muscle disease: an accelerated loss of muscle strength and mass, raising the risk of falls, fractures and early death19. It is common in older age but can start earlier1. The European working group's 2019 definition, EWGSOP2, puts strength first: low strength makes sarcopenia probable, low muscle quantity or quality confirms it, and poor physical performance on top makes it severe1. A 2024 global consensus (GLIS) named muscle mass, muscle strength and muscle-specific strength (strength per unit of muscle) as its parts, moved physical performance to an outcome rather than a part of the definition, and left its own cut-offs still to come2.

TestWhat it measuresLow in menLow in women
Grip strength (hand dynamometer)StrengthUnder 27 kg (60 lb)Under 16 kg (35 lb)
Five chair rises, no armsLeg strengthOver 15 secondsOver 15 seconds
Arm and leg muscle (ASM) by DXA or BIAMuscle quantityUnder 20 kgUnder 15 kg
ASM divided by height squaredMuscle quantityUnder 7.0 kg/m²Under 5.5 kg/m²
Usual walking speedPerformance (severity)0.8 m/s or slower0.8 m/s or slower
Short Physical Performance BatteryPerformance (severity)8 points or fewer (of 12)8 points or fewer (of 12)
Timed up and goPerformance (severity)20 seconds or more20 seconds or more

These are EWGSOP2's cut-offs as corrected in 2019 (the women's ASM/height² mark is under 5.5, not the 6.0 first printed), set mostly from European reference data1. Asian and US groups use different numbers, which is one reason prevalence estimates swing from 10% to 27% in adults over 60 depending on the definition3. Your clinician reads your own results.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's Food section sets a daily protein target from your weight and goal, or the number you choose, and counts the protein in each meal you log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

How fast do you lose muscle with age?

Slowly at first, then faster, and strength goes faster than size. Across studies, muscle mass fell by a median of 0.47% a year in men and 0.37% in women; at 75 the loss runs about 0.8 to 1% a year in men and 0.6 to 0.7% in women4. Strength at 75 falls 3 to 4% a year in men and 2.5 to 3% in women, two to five times faster than mass, and weak strength predicts disability and death more consistently than low mass does4. That is why the tests now start with grip and the chair.

How do you test your own leg strength at home?

The chair stand test is EWGSOP2's stand-in for leg strength, and it needs only a chair and a timer1.

  1. Put a firm chair without arms against a wall, and have someone beside you the first time if your balance is unsure.
  2. Sit with your feet flat and your arms crossed over your chest.
  3. Start the timer and stand fully up and sit back down five times, as fast as you safely can, without using your arms1.
  4. Stop the timer as you sit the fifth time. Over 15 seconds is EWGSOP2's mark for low strength1.
  5. Write the time down and repeat the test every few months; a slow time makes sarcopenia probable, and confirming it takes a clinician's muscle measurement, such as a DXA or BIA scan1.

When to get help If you have had a fall, your time is over 15 seconds, or stairs and chairs are getting harder month by month, ask your clinician for a sarcopenia assessment.

Does strength training slow sarcopenia?

Yes, and it is the only treatment with a strong recommendation. The international ICFSR guideline strongly recommends resistance-based exercise for sarcopenia and gives protein only a conditional one5. In 49 studies of 1,328 adults over 50, resistance training added 1.1 kg (2.4 lb) of lean mass on average; higher-volume programs added more, and the oldest people gained somewhat less6.

In people who already have sarcopenia, a network meta-analysis of 42 trials (3,728 people, median age 73, median 12 weeks) found that resistance exercise, alone or with aerobic and balance work, gave the largest gains in quality of life compared with usual care. Against usual care, resistance plus balance training, with or without nutrition, raised walking speed by 0.16 m/s, above the 0.1 m/s the authors count as a meaningful change, and the same training plus nutrition raised grip by 4.19 kg (one trial of 64 people), near the 5 kg they count as meaningful7. The US guidelines ask every adult for muscle-strengthening work at least 2 days a week8.

A light program may not move people who are already fit. In DO-HEALTH, 2,157 healthy, mobile adults over 70 did a home strength program for three years, and their physical performance score did not differ from the control group's13. Our reading of the two: training shows most in people who start weak.

Commonly reported: people who start lifting in their 60s and 70s say stairs and getting out of a chair feel easier within weeks, well before the mirror shows any change, and that the first month brings soreness that fades as sessions become routine.

How much protein do older adults need for muscle?

More than the 0.8 g per kg that younger adults need. The PROT-AGE group recommends at least 1.0 to 1.2 g per kg of body weight a day after 65, 1.2 g or more for people who exercise, and 1.2 to 1.5 g for most older adults with an acute or chronic illness; people with severe kidney disease (eGFR under 30) not on dialysis are the exception and may need less9. At 150 lb (68 kg), 1.0 to 1.2 g per kg is 68 to 82 g a day.

Protein works through training. Across 49 trials of 1,863 healthy adults, extra protein during resistance training added 0.30 kg of fat-free mass and 2.49 kg to a one-rep maximum; the gain stopped rising at about 1.6 g per kg a day, and it shrank with age10. Our guide to protein per day works out the grams at any weight.

PepVault's Food section sets a daily protein target from your weight and goal, or the number you choose, and counts the protein in each meal you log. Track your food in PepVault

Does creatine help older muscle?

Yes, when it sits beside training. In 22 trials of 721 adults aged 57 to 70 on average, training two or three days a week for 7 to 52 weeks, creatine added 1.37 kg (3.0 lb) more lean mass than training with placebo, and raised chest press strength (SMD 0.35) and leg press strength (SMD 0.24)11. SMD, the standardised mean difference, puts different strength tests on one scale; 0.2 is small and 0.5 moderate. Its effects on memory, bone and the kidneys are in our guide to creatine beyond muscle.

Does vitamin D slow muscle loss?

A little, and mostly for people who are low. Pooling 30 trials of 5,615 people, vitamin D gave a small gain in strength (SMD 0.17) and none in muscle mass or power; the strength gain was larger in people starting below 30 nmol/L (12 ng/mL) and in people 65 and older12. In DO-HEALTH, 2,000 IU a day for three years did not change physical performance in adults over 7013. The ICFSR guideline makes no recommendation for vitamin D as a sarcopenia treatment5.

PepVault's bloodwork logs vitamin D (25-OH) and total and free testosterone with each panel's date, so every new result sits on a trend beside the last. Log it in PepVault

Do testosterone or the muscle drugs work for sarcopenia?

They build lean mass, but none has yet made people clearly more able, and none is approved for sarcopenia; the ICFSR guideline makes no recommendation for anabolic hormones5. Myostatin and activin are the body's brakes on muscle growth, and the newer drugs block them.

DrugWho, and for how longWhat changed
Testosterone gel (TTrials)14790 men 65 and older with testosterone under 275 ng/dL, 1 yearWalking 50 m farther in 6 minutes: 20.5% vs 12.6% across all three trials, but no significant difference in the physical function trial itself
Testosterone gel (TOM)15209 men 65 and older with limited mobility, 6 monthsLeg press, chest press and loaded stair climbing improved; stopped early with cardiovascular events in 23 men vs 5
Myostatin antibody LY249565517201 adults 75 and older who had fallen, 24 weeksArm and leg lean mass +0.43 kg vs placebo; stair climbing, chair rise with arms and fast walking speed better, judged at the trial's looser p < 0.1 for function (only the 12-step stair test reached p < 0.05); other tests unchanged
Bimagrumab, an activin receptor blocker18180 adults 70 and older with sarcopenia, 24 weeks, both groups on diet and home exerciseLean mass +7% vs +1%; performance score +1.34 vs +1.03 points, not a significant difference

The heart question for testosterone has a larger answer now. In TRAVERSE, 5,246 men aged 45 to 80 with low testosterone and heart risk had major cardiac events at 7.0% on testosterone and 7.3% on placebo, with more atrial fibrillation, acute kidney injury and pulmonary embolism on testosterone16. The bimagrumab trial's authors draw the lesson themselves: lean mass rose 6% more than on placebo, yet function improved in both groups, and they conclude that diet and exercise can reduce sarcopenia's effects18. Who should take testosterone is covered in our guide to raising testosterone, and the new myostatin trials beside weight-loss drugs in our guide to muscle on a GLP-1.

What should you do first?

Train for strength at least twice a week, eat enough protein to back it, and check vitamin D if you have reason to be low58912. Exercise is the mainstay of treatment, but not everyone can do it, which is why other treatments are still being sought19. Retest grip or the chair stand every few months: strength falls fastest, and it is the number the definitions now trust most14.

PepVault logs your weight beside body fat from a smart scale or a tape check-in, so a change on the scale shows next to the change in fat while you train. Track your weight in PepVault

Track it in the app

Sources

  1. Cruz-Jentoft AJ et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age Ageing. 2019. PubMed 30312372
  2. Kirk B et al. The conceptual definition of sarcopenia: Delphi consensus from the Global Leadership Initiative in Sarcopenia (GLIS). Age Ageing. 2024. PubMed 38520141
  3. Petermann-Rocha F et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022. PubMed 34816624
  4. Mitchell WK et al. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. 2012. PubMed 22934016
  5. Dent E et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): screening, diagnosis and management. J Nutr Health Aging. 2018. PubMed 30498820
  6. Peterson MD et al. Influence of resistance exercise on lean body mass in aging adults: a meta-analysis. Med Sci Sports Exerc. 2011. PubMed 20543750
  7. Shen Y et al. Exercise for sarcopenia in older people: a systematic review and network meta-analysis. J Cachexia Sarcopenia Muscle. 2023. PubMed 37057640
  8. US Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition: top 10 things to know. 2018. odphp.health.gov
  9. Bauer J et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013. PubMed 23867520
  10. Morton RW et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. Br J Sports Med. 2018. PubMed 28698222
  11. Chilibeck PD et al. Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults: a meta-analysis. Open Access J Sports Med. 2017. PubMed 29138605
  12. Beaudart C et al. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2014. PubMed 25033068
  13. Bischoff-Ferrari HA et al. Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. JAMA. 2020. PubMed 33170239
  14. Snyder PJ et al. Effects of testosterone treatment in older men (the Testosterone Trials). N Engl J Med. 2016. PubMed 26886521
  15. Basaria S et al. Adverse events associated with testosterone administration (the TOM trial). N Engl J Med. 2010. PubMed 20592293
  16. Lincoff AM et al. Cardiovascular safety of testosterone-replacement therapy (TRAVERSE). N Engl J Med. 2023. PubMed 37326322
  17. Becker C et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2015. PubMed 26516121
  18. Rooks D et al. Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial. JAMA Netw Open. 2020. PubMed 33074327
  19. Sayer AA et al. Sarcopenia. Nat Rev Dis Primers. 2024. PubMed 39300120

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo